Apellis Pharmaceuticals ^{Priced, Nasdaq: APLS}

We are a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the immune system's complement system at the level of C3, the central protein in the complement cascade. We believe that this approach has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases. Our lead product candidate, APL-2, is an analog of the cyclic peptide compstatin, based on technology exclusively licensed from the University of Pennsylvania. We believe that APL-2 has the potential to be a best-in-class treatment that may address the limitations of existing treatments or provide a treatment option where there currently is none. APL-2 is in clinical trials for geographic atrophy in age-related macular degeneration (GA) and paroxysmal nocturnal hemoglobinuria (PNH), and we plan to pursue additional complement-dependent diseases. In our ongoing Phase 2 trial of APL-2 in patients with GA, treatment with APL-2 resulted in a significant reduction in the rate of GA lesion growth over 12 months, and in our two ongoing Phase 1b trials in PNH, APL-2 achieved improvements in transfusion dependency, hemoglobin levels and other hematological indicators that we believe are clinically meaningful.